Farr Miller & Washington LLC DC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 90,641 shares of the biopharmaceutical company’s stock after buying an additional 4,726 shares during the quarter. Farr Miller & Washington LLC DC’s holdings in Pfizer were worth $3,283,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Hamilton Capital Management Inc. purchased a new stake in Pfizer in the fourth quarter valued at approximately $207,000. Landscape Capital Management L.L.C. purchased a new stake in Pfizer in the fourth quarter valued at approximately $638,000. Geode Capital Management LLC grew its holdings in Pfizer by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company’s stock valued at $2,281,563,000 after purchasing an additional 1,881,570 shares during the period. Financial Gravity Companies Inc. purchased a new stake in Pfizer in the fourth quarter valued at approximately $281,000. Finally, Mitchell Capital Management Co. purchased a new stake in Pfizer in the fourth quarter valued at approximately $240,000. Institutional investors and hedge funds own 69.53% of the company’s stock.
In other news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ian C. Read sold 132,312 shares of the business’s stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total transaction of $4,764,555.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 380,349 shares of company stock worth $13,829,340. Corporate insiders own 0.06% of the company’s stock.
Shares of Pfizer opened at $35.68 on Friday, Marketbeat.com reports. The company has a market cap of $213.65 billion, a price-to-earnings ratio of 13.46, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. Pfizer Inc. has a fifty-two week low of $31.67 and a fifty-two week high of $39.43.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business had revenue of $12.91 billion for the quarter, compared to analysts’ expectations of $13.14 billion. During the same period in the previous year, the company posted $0.69 earnings per share. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, May 10th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.81%. Pfizer’s payout ratio is currently 51.32%.
PFE has been the subject of a number of recent analyst reports. SunTrust Banks restated a “hold” rating and issued a $40.00 target price (up from $33.00) on shares of Pfizer in a report on Monday, January 29th. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “hold” rating in a report on Monday, February 26th. Morningstar set a $38.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. BMO Capital Markets set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, March 6th. Finally, Bank of America set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $40.08.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.